Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

View source ↗

Summary

A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no results or active statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Breast Cancer
• Hepatocellular Carcinoma
• Multiple Myeloma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer

Snippet

Sponsor: Travera Inc | Conditions: Stage III Breast Cancer, Stage IV Breast Cancer | Status: WITHDRAWN